Last reviewed · How we verify
RBS2418
At a glance
| Generic name | RBS2418 |
|---|---|
| Sponsor | Riboscience, LLC. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer (PHASE2)
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors (PHASE1)
- Expanded Access RBS2418 Treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBS2418 CI brief — competitive landscape report
- RBS2418 updates RSS · CI watch RSS
- Riboscience, LLC. portfolio CI